Dana-Farber Cancer Institute, Boston, MA, USA.
Genmab, Plainsboro, NJ, USA.
Leuk Lymphoma. 2024 Nov;65(11):1623-1633. doi: 10.1080/10428194.2024.2371472. Epub 2024 Jul 16.
This study used COTA de-identified data (2010-2021) of patients in the US to explore outcomes of novel therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in real-world settings. Demographics, clinical characteristics, and clinical outcomes of patients with R/R DLBCL who received novel treatments including chimeric antigen receptor T-cell (CAR T) therapy and tafasitamab- or polatuzumab-based therapies were evaluated. Overall, 175 patients with R/R DLBCL were analyzed; 73, 69, and 27 received CAR T therapy, polatuzumab-based regimens, and tafasitamab-based regimens, respectively. In patients who had ≥1 prior lines of therapy (i.e. starting second-line or later therapy; 2 L+), CAR T, polatuzumab-based regimens, and tafasitamab-based regimens achieved a median overall survival of 26.5, 7.8, and 6.3 months, respectively. Outcomes were particularly poor for patients with relapse following CAR T, indicating that polatuzumab- and tafasitamab-based regimens in 2 L + R/R DLBCL have suboptimal outcomes in the real world. Additional treatment options are needed.
本研究使用 COTA 去识别数据（2010-2021 年），在美国探索了新型疗法在复发/难治性弥漫性大 B 细胞淋巴瘤（DLBCL）患者中的真实世界疗效。评估了接受新型治疗（包括嵌合抗原受体 T 细胞（CAR T）疗法和基于 tafasitamab 或 polatuzumab 的疗法）的 R/R DLBCL 患者的人口统计学、临床特征和临床结局。总体上，分析了 175 名 R/R DLBCL 患者；73、69 和 27 名患者分别接受了 CAR T 治疗、基于 polatuzumab 的方案和基于 tafasitamab 的方案。在≥1 线治疗（即开始二线或更后线治疗；2L+）的患者中，CAR T、基于 polatuzumab 的方案和基于 tafasitamab 的方案的中位总生存期分别为 26.5、7.8 和 6.3 个月。对于 CAR T 治疗后复发的患者，结局特别差，表明 polatuzumab 和 tafasitamab 为基础的方案在 2L+R/R DLBCL 中的真实世界疗效并不理想。需要更多的治疗选择。
